Circulating levels of RANTES in human immunodeficiency virus type 1 infection: Effect of potent antiretroviral therapy

Journal of Infectious Diseases

Volumn 177, Issue 4, 1998, Pages 1091-1096

  Aukrust, Pål ^a   Müller, Fredrik ^b   Froøland, Stig S ^b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD8 ANTIGEN; INDINAVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RANTES; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DRUG EFFECT; DRUG POTENCY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 0031967228     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/517402     Document Type: Article

References (15)

1. Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines - CXC and CC chemokine. Adv Immunol 1994;55:97-179.
2. Strieter RM, Standiford TJ, Huffnagle GB, Colletti LM, Lukacs NW, Kunkel SL. The good, the bad, and the ugly. The role of chemokines in human diseases. J Immunol 1996;356:3583-6.
3. + T cells. Science 1995;270:1811-5.
4. + T cells. Immnol Today 1996;17:217-24.
5. McKenzie SW, Dallalio G, North M, Frame P, Means RT Jr. Serum chemokine levels in patients with non-progressive HIV infection. AIDS 1996;10:F29-F33.
6. Zanussi S, D'Andera M, Simonelli C, Tirelli U, De Paoli P. Serum levels of RANTES and MIP-1a in HIV-positive long-term survivors and progressons patients. AIDS 1996;10:1431-2.
7. + lymphocytes associated with disturbed intracellular redox balance in human immunodeficiency virus type 1 infection. Blood 1995;86:258-67.
8. Aukrust P, Hestdal K, Lien E, et al. Effects of intravenous immunoglobulin in vivo on abnormally increased tumor necrosis factor-α activity in patients with human immunodeficiency virus type 1 infection. J Infect Dis 1997;176:913-23.
9. Holme PA, Müller F, Solum NO, Brosstad F, Frøland SS, Aukrust P. Enhanced activation of platelets with abnormal release of RANTES in HIV-1 infection. FASEB J 1998 (in press).
10. Kelleher AD, Carr A, Zaunders J, Cooper DA. Alterations in the immuneresponse of the human immunodeficiency virus (HIV) - infected subject treated with a HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996;123:321-6.
11. Hammer SH, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
12. + T cells of HIV-infected individuals is regulated by a balance between the viral suppressive effects of endogenous b-chemokines and the viral inductive effects of other endogenous cytokines. Proc Natl Acad Sci USA 1996;93:14076-81.
13. Bisset LR, Rothen M, JollerJemelka HI, Dubs RW, Grob PJ, Opravil M. Change in circulating levels of the chemokines macrophage inflammatory proteins 1a and 1b, RANTES, monocyte chemotactic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir. AIDS 1997;11:485-91.
14. Moriuchi H, Moriuchi M, Fauchi AS. Nuclear factor-κB potently upregulates the promoter activity of RANTES, a chemokine that blocks HIV infection. J Immunol 1997;158:3483-91.
15. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1 - infected individuals. J Exp Med 1987;185:621-8.